Colorectal cancer remains a leading cause of cancer death, with incidence rising among older adults. One of the most pressing clinical questions has been whether elderly patients should receive oxaliplatin, a standard component of adjuvant chemotherapy that is known to cause serious side effects. To address this, Dr. Jun Woo Bong conducted a large-scale population study. The team examined health records from more than 8,500 patients with stage II or III colorectal cancer who underwent surgery followed by chemotherapy between 2014 and 2016. Patients were divided into two groups: those treated with oxaliplatin-based combinations, and those given standard chemotherapy alone....